DAFNA Capital Management’s Gyre Therapeutics GYRE Stock Holding History

DAFNA Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-630	Closed	-$86K	–	68
2016 Q3	$86K	Hold	630	–	–	0.06%	70
2016 Q2	$108K	Hold	630	–	–	0.09%	85
2016 Q1	$119K	Hold	630	–	–	0.1%	82
2015 Q4	$222K	Hold	630	–	–	0.2%	64
2015 Q3	$330K	Buy	630 +41	+7%	+$62.5K	0.33%	64
2015 Q2	$1.29M	Sell	589 -2	-0.3%	-$4.01K	1.09%	31
2015 Q1	$1.38M	Hold	591	–	–	1.06%	28
2014 Q4	$1.22M	Buy	591 +421	+248%	+$811K	0.97%	29
2014 Q3	$339K	Buy	+170	New	+$420K	0.34%	45

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

CCM

Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

DAFNA Capital Management's GYRE Position: Q4 2016 in Review

DAFNA Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2016, closing a stake of 630 shares — an estimated $86K sold.

DAFNA Capital Management first reported a position in GYRE in Q3 2014 and held it in 9 quarters. The position peaked at $1.38M in Q1 2015. 27 funds tracked by Wall St. Rank hold GYRE as of Q4 2016.

DAFNA Capital Management reported no remaining Gyre Therapeutics position as of Q4 2016 after selling out during the quarter.
DAFNA Capital Management sold 630 Gyre Therapeutics shares in Q4 2016, an estimated $86K.
DAFNA Capital Management first reported a position in Gyre Therapeutics in Q3 2014 and held it in 9 quarters.
DAFNA Capital Management's Gyre Therapeutics position peaked at $1.38M in Q1 2015.
27 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2016.

Based on DAFNA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.